Why are researchers investigating BG00012?
BG00012 is an oral formulation of dimethyl fumarate (DMF). Preliminary experimental findings suggest that DMF may activate the Nrf2 pathway. The Nrf2 pathway is a central mechanism by which cells are protected from metabolic and inflammatory stress. In addition to assessing whether BG00012 can reduce relapses, both studies will also assess the effects of BG00012 on disability progression and disease activity as measured by magnetic resonance imaging (MRI).
